Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-80

Never deal with the devil and never put all your eggs in one basket comes to mind here, looks to me that the BOD wants to make sure that they can get their 93 across the line come what may, would be a shame to miss out on some magnificent partnerships down the track because of taking crumbs now. As for early t/o moving from the 1/2 range to 2/3 range that all depends on your terminology of near term, the greedy seven need it by July and if one were to occur the price would need to be around $1.50 to get a $3 t/o imo not likely without revenue. I cannot imagine shareholders accepting less than $1.50 so any t/o less than that unlikely to succeed.
in other words by July.......no takeover.....no 20 mill revenue, which will suit a lot of people fine.
imo
dyor